L V Prasad Eye Institute, MIT-India host Humanistic Co-Design Workshop

IMT News Desk
IMT News Desk
· 3 min read
healthcare

LVPEI Center for Innovation and MIT (Massachusetts) in sponsorship from MIT-India (Massachusetts) and L V Prasad Eye Institute (Hyderabad) hosted a three-day workshop on Humanistic Co-Design for the Visually Impaired in Hyderabad. This was an ideal platform for design and engineering students to directly collaborate with people who have visual disabilities, examine their problems and identify solutions. This tour was part of the annual MIT India program by the MIT (Massachusetts) team to a few Institutes in India to understand disability needs and Co-design.

Humanistic Co-design nurtures the thought of including the motivations of the user while building solutions for them. The process begins through holistic connections with people without a design/engineering agenda and concrete designs reveal themselves through intrinsic humanity and the desire to be of service.

“The LVPEI Center for Innovation has been home to many innovations in the areas of eye care delivery, biology of the eye, surgical techniques, eye banking and children’s eye health among others over the years. LVPEI provided a platform for young minds to see their innovations from prototype to product through this workshop, and we saw an amazing range of possibilities,” said Raghu Gullapalli, Executive Director, Emerging Technologies and Business Development, LVPEI Center for Innovation.

Quality healthcare is still inaccessible in low resource areas. These innovations are bridging the gaps between healthcare centers and low resource areas through self-contained and low-cost alternatives. Research and education play a vital role in the advancement of medicine. These innovations enhance the medical education experience and enable global standardization of clinical research, allowing for speedy translation.

Vision Rehabilitation is an integral part of the L V Prasad Eye Institute’s pyramidal model of eye care delivery. The comprehensive services range from assessment and prescription of low vision devices to social, educational, and vocational rehabilitation through training or re-training patients with low vision and blindness to the highest possible level of their functional ability.

During this workshop, participants worked with focus groups, rehabilitation experts and professionals from various domains to ideate and rapid prototype. The participants were mentored by Dr. Kyle Keane, Lecturer and Research Scientist from MIT, who specializes in computational materials science, human-centered design, and engineering technology that helps people with disabilities, along with Dr. Beula Christy, Head of Centre for Rehabilitation of the Blind and Visually Impaired at LVPEI.

The Humanistic Co-design Initiative is a cooperative of individuals, organizations and institutions working together to increase awareness about how designers, makers, and engineers can apply their skills in collaboration with people who have disabilities through the Humanistic Co-design Process to develop new and innovative assistive technologies. The workshop was co mentored by the other MIT faculty and team from LVPEI Center for Innovation.

Read Next

Biogen to push ahead with experimental Alzheimer’s drug despite mid-stage trial miss
News
May 15, 2026

Biogen to push ahead with experimental Alzheimer’s drug despite mid-stage trial miss

Biogen Inc. has said it will advance its experimental Alzheimer’s therapy diranersen into late-stage trials even though the drug failed to meet the primary endpoint in a mid-stage (Phase 2) study in patients with early-stage disease. The antisense therapy targets tau, a key protein linked to neurodegeneration, and showed robust reductions in tau levels along […]
Article by: IMT News Desk
Akums Reports Strong Q4 FY26 Performance; EBITDA Surges 62%, Board Recommends Dividend
News
May 15, 2026

Akums Reports Strong Q4 FY26 Performance; EBITDA Surges 62%, Board Recommends Dividend

Akums Drugs & Pharmaceuticals Ltd., India’s largest Contract Development and Manufacturing Organisation (CDMO), has reported a robust financial performance for the fourth quarter and full year ended March 31, 2026, driven by strong growth in its core CDMO business and improved operational efficiencies. Q4 FY26: Profitability Outpaces Revenue Growth Akums posted an operating revenue of […]
Article by: IMT News Desk
Alembic Pharmaceuticals announces USFDA Tentative Approval for Darolutamide Tablets
News
May 14, 2026

Alembic Pharmaceuticals announces USFDA Tentative Approval for Darolutamide Tablets

Alembic Pharmaceuticals Limited (Alembic) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Darolutamide Tablets, 300 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Nubeqa Tablets, 300 mg, of Bayer HealthCare Pharmaceuticals Inc. (Bayer). Darolutamide is an androgen […]
Article by: IMT News Desk
Lilly launches Lormalzi® (Donanemab) for the treatment of early symptomatic Alzheimer’s Disease in India
News
May 14, 2026

Lilly launches Lormalzi® (Donanemab) for the treatment of early symptomatic Alzheimer’s Disease in India

Eli Lilly and Company (India) Pvt. Ltd. has announced the launch of Lormalzi® (donanemab, 350 mg/20 mL IV vial) in India, following marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) for the treatment of Alzheimer’s disease with mild cognitive impairment or those in the mild dementia stage of disease. Lormalzi® is the first […]
Article by: IMT News Desk